WELLESLEY, Mass.--(BUSINESS WIRE)--NormOxys Inc., a biotechnology company developing a novel class of small molecule drugs which enhance the body’s ability to deliver oxygen to diseased tissues and organs, today announced that OXY111A, its clinical stage candidate for the treatment of chronic heart failure and cancer, has been selected as one of Windover’s “Top 10 Cardiovascular/Metabolic Projects to Watch.” Along with inclusion in the “Top 10 to Watch” list, NormOxys is making a presentation today at Windhover’s Therapeutic Area Partnerships meeting, which is being held at the Westin Copley Place in Boston.
